All Blogs

Aug 02, 2022

Bristol-Myers Squibb’s Opdivo and Yervoy Combo Fails in Phase III Trial Bristol-Myers Squibb has reported that their Opdivo and Yervoy checkpoint inhibitor combo failed a phase III trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), the most frequent type of kidney cancer. The CheckMate -914...

Aug 01, 2022

Though a rare disease, generalized myasthenia gravis (gMG) still affects around 60,000 people in the US and another 100,000 in EU-5 and Japan. As per our analysis, the total diagnosed prevalent cases of gMG were approx 116K in the 7MM in 2021. These numbers are further estimated to increase by 2032. Moreover, t...

Jul 29, 2022

Key Highlights The US approval of Jynarque added the much-needed push to the ADPKD treatment market.In the coming years, Bardoxolone methyl is expected to be an effective therapy for ADPKD treatment.The current ADPKD treatment only aims to delay the disease progression rather than completely cure the disease, wh...

Jul 28, 2022

ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise™ System for the Treatment of Hypertension On July 26, 2022, ReCor Medical, Inc., a completely owned subsidiary of Otsuka Medical Devices Co., Ltd., with its headquarters in Palo Alto,...

Jul 27, 2022

Around 50 million people in the United States live with—and suffer from—chronic pain. The prevalence of chronic pain has grown significantly over the past few decades due to lifestyle changes, traumatic injury, a rise in critical surgeries, and growth in the overweight or obese population, among serval other underl...

Jul 26, 2022

FDA Approves Incyte’s Opzelura as First Vitiligo Therapy The US Food and Drug Administration has approved Incyte’s Opzelura cream 1.5% for the topical treatment of non-segmental vitiligo in adult and paediatric patients 12 years of age and older. With this approval, Opzelura is the first and only FDA-approved...

Jul 25, 2022

Bronchopulmonary Dysplasia is the most common long-term respiratory morbidity of low-weight or premature infants, with the risk of development proportional to the degree of prematurity. It is also referred to as chronic lung disease of premature babies. It is a chronic respiratory disease that often occurs in low-w...

Jul 22, 2022

Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landscape changed the market once dominated by Roche.Moving forward, RVO’s robust pipeline, along with several VEGF inhibitors, creates trouble for the big ones; Lucentis and Eylea. Retinal vein occlusion is the second most common s...

Jul 21, 2022

Orthox Obtains MHRA Approval to Commence FFLEX Study  On July 14, 2022, Orthodox Ltd, a clinical-stage company created medical implants to treat orthopedic problems including damaged knee articular cartilage. It was founded in 2008 by life scientist, Dr. Nick Skaer, and knee surgeon, Professor Oliver Kessle...

Jul 27, 2026

For decades, the idea of microscopic robots travelling through the human bloodstream to hunt down disease sounded like pure science fiction. That idea is now a serious field of biomedical engineering. Medical nanorobotics sits at the intersection of nanotechnology, robotics, molecular biology, materials science, an...